Indeed, genetic inhibition of DGAT1 in vivo suppresses tumor growth and prolongs the survival of glioblastoma-bearing mice, demonstrating that targeting DGAT1 may offer therapeutic benefit for patients with glioblastoma [49]. This evidence concerns the gene DGAT1 and neoplasm.